Drug giant agrees to acquire sleep-aid developer Hypnion.
|
Israel Roundup: Tech startups snag highest amount in five years; Actelis, Wikio, Multipon, and Yoggie complete rounds; Intel confirms closure of Jerusalem plant.
|
It’s pharmaceutical giant’s third drug development alliance in India in six months.
|
Two treatments for Parkinson’s found to harm heart valves.
|
Concerned by consumer distrust, Google, eBay, Microsoft seek a law to combat Internet fraud.
|
Dow-funded research suggests silicone implants don’t increase risk of breast cancer.
|
Drug maker spurns $17.4-billion unsolicited offer, saying it undervalues the company.
|
Sanofi-Aventis’ $3.5-billion blood-thinning drug is no better than aspirin.
|
Panel recommends stringent warning labels after finding child fatalities linked to attention deficit disorder drugs like Ritalin.
|
Drug maker receives long-awaited FDA nod on its Exubera insulin inhalant, but leaks word a little early.
|
Some 15 startups report funding Tuesday as venture capitalists disburse some of the money raised last year.
|
CEO of biotech firm Protemix describes his company’s yin-yang approach to creating drugs for diabetes-related complications.
|
Drug maker expects 2006 earnings to beat Wall Street industry expectations.
|
Week of December 27, 2004: Prozac papers send Eli Lilly stock a tumblin’, Oracle replaces PeopleSoft’s top tier, a new Trojan horse virus lurks, and Gartner buys Meta.
|
Lucky for drug companies, we’re desperate to live – and look good – for a long, long time.
|